Načítá se...
Use and Spending on Biologic Disease-modifying Anti-rheumatic Drugs for Rheumatoid Arthritis among U.S. Medicare Beneficiaries
OBJECTIVES: Biologic therapies have assumed an important role in treating rheumatoid arthritis (RA). We sought to investigate use, spending, and patient cost-sharing for Medicare beneficiaries using biologic drugs for RA, comparing patients exposed to minimal cost-sharing because of a Part D low-inc...
Uloženo v:
| Vydáno v: | Arthritis Care Res (Hoboken) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4573380/ https://ncbi.nlm.nih.gov/pubmed/25776035 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.22580 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|